Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Palisade Bio (PALI) Gains from Sales and Divestitures (2016 - 2023)

Palisade Bio (PALI) has disclosed Gains from Sales and Divestitures for 7 consecutive years, with $61120.0 as the latest value for Q4 2023.

  • On a quarterly basis, Gains from Sales and Divestitures changed N/A to $61120.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $61120.0, a N/A change, with the full-year FY2023 number at $61120.0, changed N/A from a year prior.
  • Gains from Sales and Divestitures was $61120.0 for Q4 2023 at Palisade Bio, up from $12662.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $61120.0 in Q4 2023 to a low of $3814.0 in Q4 2020.
  • A 4-year average of $16355.2 and a median of $8167.5 in 2019 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: plummeted 87.81% in 2019, then crashed 44.0% in 2021.
  • Palisade Bio's Gains from Sales and Divestitures stood at $8835.0 in 2019, then crashed by 56.83% to $3814.0 in 2020, then grew by 10.12% to $4200.0 in 2021, then surged by 1355.24% to $61120.0 in 2023.
  • Per Business Quant, the three most recent readings for PALI's Gains from Sales and Divestitures are $61120.0 (Q4 2023), $12662.0 (Q2 2023), and $4200.0 (Q1 2021).